WO2004000209A2 - Administration of therapeutic viruses - Google Patents
Administration of therapeutic viruses Download PDFInfo
- Publication number
- WO2004000209A2 WO2004000209A2 PCT/US2003/016474 US0316474W WO2004000209A2 WO 2004000209 A2 WO2004000209 A2 WO 2004000209A2 US 0316474 W US0316474 W US 0316474W WO 2004000209 A2 WO2004000209 A2 WO 2004000209A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus
- surface area
- dose
- per square
- square meter
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/518,732 US20050220818A1 (en) | 2002-06-21 | 2003-05-22 | Administration of therapeutic viruses |
NZ537255A NZ537255A (en) | 2002-06-21 | 2003-05-22 | Administration of therapeutic viruses |
AU2003243307A AU2003243307B2 (en) | 2002-06-21 | 2003-05-22 | Administration of therapeutic viruses |
EP03761032A EP1539230A4 (en) | 2002-06-21 | 2003-05-22 | Administration of therapeutic viruses |
JP2004515715A JP2006511450A (en) | 2002-06-21 | 2003-05-22 | Administration of therapeutic virus |
CA002489523A CA2489523A1 (en) | 2002-06-21 | 2003-05-22 | Administration of therapeutic viruses |
MXPA04012881A MXPA04012881A (en) | 2002-06-21 | 2003-05-22 | Administration of therapeutic viruses. |
IL16586004A IL165860A0 (en) | 2002-06-21 | 2004-12-19 | Administration of therapeutic viruses |
US12/409,711 US20090180993A1 (en) | 2002-06-21 | 2009-03-24 | Administration of therapeutic viruses |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39063202P | 2002-06-21 | 2002-06-21 | |
US60/390,632 | 2002-06-21 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/409,711 Continuation US20090180993A1 (en) | 2002-06-21 | 2009-03-24 | Administration of therapeutic viruses |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004000209A2 true WO2004000209A2 (en) | 2003-12-31 |
WO2004000209A3 WO2004000209A3 (en) | 2005-03-03 |
Family
ID=30000590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/016474 WO2004000209A2 (en) | 2002-06-21 | 2003-05-22 | Administration of therapeutic viruses |
Country Status (11)
Country | Link |
---|---|
US (2) | US20050220818A1 (en) |
EP (2) | EP1539230A4 (en) |
JP (1) | JP2006511450A (en) |
AU (1) | AU2003243307B2 (en) |
CA (1) | CA2489523A1 (en) |
IL (1) | IL165860A0 (en) |
MX (1) | MXPA04012881A (en) |
NZ (1) | NZ537255A (en) |
RU (1) | RU2314830C2 (en) |
WO (1) | WO2004000209A2 (en) |
ZA (1) | ZA200410229B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005113018A2 (en) | 2004-04-27 | 2005-12-01 | Wellstat Biologics Corporation | Cancer treatment using viruses and camptothecins |
US7767200B2 (en) | 2005-07-14 | 2010-08-03 | Wellstat Biologics Corporation | Cancer treatment using viruses, fluoropyrimidines and camptothecins |
US8377450B2 (en) | 2009-11-30 | 2013-02-19 | United Cancer Research Institute | Clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer |
WO2021258008A1 (en) * | 2020-06-19 | 2021-12-23 | Immunacor Llc | Compositions and methods for treating and preventing viral infection |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013052915A2 (en) | 2011-10-05 | 2013-04-11 | Genelux Corporation | Method for detecting replication or colonization of a biological therapeutic |
US20140087362A1 (en) | 2012-03-16 | 2014-03-27 | Aladar A. Szalay | Methods for assessing effectiveness and monitoring oncolytic virus treatment |
US20130280170A1 (en) | 2012-04-20 | 2013-10-24 | Aladar A. Szalay | Imaging methods for oncolytic virus therapy |
WO2014055960A1 (en) | 2012-10-05 | 2014-04-10 | Genelux Corporation | Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes |
US10238700B2 (en) | 2014-01-02 | 2019-03-26 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
NZ730563A (en) | 2014-10-14 | 2019-05-31 | Halozyme Inc | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
KR20190006495A (en) | 2016-04-15 | 2019-01-18 | 알파인 이뮨 사이언시즈, 인코포레이티드 | CD80 variant immunoregulatory proteins and uses thereof |
KR20230051602A (en) | 2016-04-15 | 2023-04-18 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Icos ligand variant immunomodulatory proteins and uses thereof |
US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
CN110088127A (en) | 2016-07-28 | 2019-08-02 | 高山免疫科学股份有限公司 | CD155 variant immune modulator and application thereof |
AU2017345764A1 (en) | 2016-10-20 | 2019-05-02 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
CN110546265A (en) | 2017-02-09 | 2019-12-06 | 因达普塔治疗公司 | Engineered Natural Killer (NK) cells and compositions and methods thereof |
EP3596116B1 (en) | 2017-03-16 | 2023-09-06 | Alpine Immune Sciences, Inc. | Pd-l1 variant immunomodulatory proteins and uses thereof |
AU2018235838B2 (en) | 2017-03-16 | 2023-12-14 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
US11732022B2 (en) | 2017-03-16 | 2023-08-22 | Alpine Immune Sciences, Inc. | PD-L2 variant immunomodulatory proteins and uses thereof |
EA202090974A1 (en) | 2017-10-18 | 2020-08-05 | Элпайн Иммьюн Сайенсиз, Инк. | VARIANT IMMUNOMODULATING PROTEINS OF ICOS LIGAND AND ACCOMPANYING COMPOSITIONS AND METHODS |
US11505782B2 (en) | 2018-06-04 | 2022-11-22 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
CN112533621A (en) | 2018-06-04 | 2021-03-19 | 卡利迪生物治疗有限公司 | Cell-based agents for enhancing viral therapy |
WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
EP3844276A2 (en) | 2018-08-28 | 2021-07-07 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
CN113271955A (en) | 2018-11-06 | 2021-08-17 | 卡利迪生物治疗有限公司 | Enhanced systems for cell-mediated oncolytic viral therapy |
KR20210123289A (en) | 2018-11-21 | 2021-10-13 | 인답타 세라뷰틱스 인코포레이티드 | Methods and related compositions and methods for propagation of natural killer cell subsets |
JP2022510276A (en) | 2018-11-30 | 2022-01-26 | アルパイン イミューン サイエンシズ インコーポレイテッド | CD86 variant immunomodulatory protein and its use |
CA3176660A1 (en) | 2019-02-27 | 2020-09-03 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
JP2023523429A (en) | 2020-04-22 | 2023-06-05 | インダプタ セラピューティクス インコーポレイテッド | Natural killer (NK) cell compositions and methods for producing same |
TW202241479A (en) | 2020-12-30 | 2022-11-01 | 美商安迅生物製藥公司 | Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000062735A2 (en) | 1999-04-15 | 2000-10-26 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3906092A (en) * | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
ES2196026T3 (en) | 1993-04-30 | 2003-12-16 | Wellstat Biologics Corp | USE OF NDV IN THE MANUFACTURE OF A MEDICINAL PRODUCT TO TREAT CANCER. |
EP0848956A1 (en) * | 1996-12-17 | 1998-06-24 | Dimminaco Ag/Sa/Ltd. | In ovo vaccination against Newcastle Disease |
US7470426B1 (en) * | 1997-10-09 | 2008-12-30 | Wellstat Biologics Corporation | Treatment of neoplasms with viruses |
HUP0003911A3 (en) * | 1997-10-09 | 2007-11-28 | Pro Virus | Treatment of neoplasms with viruses |
US6024961A (en) * | 1997-11-14 | 2000-02-15 | Washington University | Recombinant avirulent immunogenic S typhi having rpos positive phenotype |
US20050074901A1 (en) * | 2002-02-13 | 2005-04-07 | John Castracane | Methods and assays for detecting and quantifying the human p53 inducible gene protein |
US20040131595A1 (en) * | 2002-11-05 | 2004-07-08 | Wellstat Biologics Corporation | Treating carcinoid neoplasms with therapeutic viruses |
-
2003
- 2003-05-22 EP EP03761032A patent/EP1539230A4/en not_active Withdrawn
- 2003-05-22 RU RU2005101351/14A patent/RU2314830C2/en not_active IP Right Cessation
- 2003-05-22 JP JP2004515715A patent/JP2006511450A/en not_active Ceased
- 2003-05-22 NZ NZ537255A patent/NZ537255A/en not_active IP Right Cessation
- 2003-05-22 MX MXPA04012881A patent/MXPA04012881A/en active IP Right Grant
- 2003-05-22 WO PCT/US2003/016474 patent/WO2004000209A2/en active Search and Examination
- 2003-05-22 CA CA002489523A patent/CA2489523A1/en not_active Abandoned
- 2003-05-22 EP EP10179896A patent/EP2266601A1/en not_active Withdrawn
- 2003-05-22 US US10/518,732 patent/US20050220818A1/en not_active Abandoned
- 2003-05-22 AU AU2003243307A patent/AU2003243307B2/en not_active Ceased
-
2004
- 2004-12-19 IL IL16586004A patent/IL165860A0/en unknown
- 2004-12-20 ZA ZA200410229A patent/ZA200410229B/en unknown
-
2009
- 2009-03-24 US US12/409,711 patent/US20090180993A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000062735A2 (en) | 1999-04-15 | 2000-10-26 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
Non-Patent Citations (2)
Title |
---|
J. CLIN. ONCOL., vol. 20, May 2002 (2002-05-01), pages 2251 - 2266 |
See also references of EP1539230A4 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005113018A2 (en) | 2004-04-27 | 2005-12-01 | Wellstat Biologics Corporation | Cancer treatment using viruses and camptothecins |
US9844574B2 (en) | 2004-04-27 | 2017-12-19 | Wellstat Biologics Corporation | Cancer treatment using viruses and camptothecins |
US7767200B2 (en) | 2005-07-14 | 2010-08-03 | Wellstat Biologics Corporation | Cancer treatment using viruses, fluoropyrimidines and camptothecins |
US8377450B2 (en) | 2009-11-30 | 2013-02-19 | United Cancer Research Institute | Clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer |
WO2021258008A1 (en) * | 2020-06-19 | 2021-12-23 | Immunacor Llc | Compositions and methods for treating and preventing viral infection |
Also Published As
Publication number | Publication date |
---|---|
EP1539230A4 (en) | 2007-10-31 |
US20090180993A1 (en) | 2009-07-16 |
JP2006511450A (en) | 2006-04-06 |
EP1539230A2 (en) | 2005-06-15 |
US20050220818A1 (en) | 2005-10-06 |
ZA200410229B (en) | 2006-07-26 |
IL165860A0 (en) | 2006-01-15 |
RU2314830C2 (en) | 2008-01-20 |
RU2005101351A (en) | 2005-08-10 |
EP2266601A1 (en) | 2010-12-29 |
MXPA04012881A (en) | 2005-07-05 |
AU2003243307A1 (en) | 2004-01-06 |
WO2004000209A3 (en) | 2005-03-03 |
CA2489523A1 (en) | 2003-12-31 |
AU2003243307B2 (en) | 2010-04-01 |
NZ537255A (en) | 2009-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003243307B2 (en) | Administration of therapeutic viruses | |
Markert et al. | Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12 | |
US9844574B2 (en) | Cancer treatment using viruses and camptothecins | |
JP5190958B2 (en) | Treatment of cancer using viruses, fluoropyrimidine and camptothecin | |
Ford et al. | Immunization of rats against Schistosoma mansoni using irradiated cercariae, lung schistosomula and liver-stage worms | |
US9623096B2 (en) | Virally infected hematopoietic cells and uses thereof | |
JP2006510741A (en) | Treatment of carcinoid neoplasms with therapeutic viruses | |
AU2004266102B2 (en) | Anti-cancer virus desensitization method | |
Worthington et al. | Effectiveness of an interferon stimulator in immunosuppressed mice | |
KR20060007006A (en) | Newcastle disease virus administration | |
Todd et al. | Influence of epinephrine upon plasma potassium concentration: Changes with time during constant infusion | |
CN110876759A (en) | Application of M gene mutated vesicular stomatitis virus in antitumor drugs | |
CN102917717B (en) | Anti-tumor compositions | |
CN106591368A (en) | B subgroup adenovirus 11 vector carrying IL-15R/IL-15 fusion genes and construction and application of the same | |
Li et al. | Studies on inhibition of viral oncogenesis: III. Effect of clam extracts and methotrexate on tumor formation in male and female hamsters induced by virulent and attenuated Adenovirus-12 | |
AU2004233804A1 (en) | Treating hepatocellular carcinomas using therapeutic viruses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003243307 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2489523 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 537255 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/012881 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 165860 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10518732 Country of ref document: US Ref document number: 200410229 Country of ref document: ZA Ref document number: 2004515715 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038145847 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2005101351 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003761032 Country of ref document: EP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 2003761032 Country of ref document: EP |